A 60 year old person old person is suffering from diabetes for last 10 years. a.List the biochemical investigations you should advise him as a part of regular check-up. b.Write down the biochemical reference range of those parameters. c.Explain the alternation of lipid metabolism in diabetes.
Reading File
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Reading File
Finding Sources
Finding Sources
Reading File
Reading File
I now have all the information needed to provide a comprehensive, well-cited answer. Let me compose the full response.
Biochemical Investigations for a 60-Year-Old with 10-Year Diabetes History
Part A: Biochemical Investigations for Regular Check-Up
For chronic diabetes management, investigations span glycemic control, renal function, lipid profile, and detection of complications. Based on Tietz Textbook of Laboratory Medicine (7th ed.), the standard panel includes:
1. Glycemic Control
- Fasting plasma glucose (FPG) - primary glycemic monitoring
- HbA1c (Glycated Hemoglobin) - reflects average blood glucose over the past 2-3 months; the most important long-term monitoring parameter
- Postprandial blood glucose (PPBG) - 2 hours after meals
- Fructosamine / Glycated albumin - useful when HbA1c is unreliable (e.g., haemolytic anaemia, haemoglobinopathies); reflects 2-3 week average
- 1,5-Anhydroglucitol (1,5-AG) - short-term glycemic excursion marker
2. Renal Function (Diabetic Nephropathy Screening)
- Urine microalbumin / Albumin-to-creatinine ratio (ACR) - earliest marker of diabetic nephropathy
- Urine protein (24-hour proteinuria if ACR is elevated)
- Serum creatinine - to calculate eGFR (estimated glomerular filtration rate)
- Blood urea nitrogen (BUN)
- Serum electrolytes (sodium, potassium) - especially relevant with diabetic kidney disease
3. Lipid Profile (Cardiovascular Risk)
- Total cholesterol
- LDL cholesterol
- HDL cholesterol
- Triglycerides (TG)
- VLDL (usually calculated)
4. Liver Function Tests
- ALT, AST, GGT - to screen for metabolic dysfunction-associated steatotic liver disease (MASLD/NAFLD), which is common in type 2 DM
5. Thyroid Function
- TSH - hypothyroidism is more prevalent in diabetics and worsens glycemic control and dyslipidemia
6. Complete Blood Count (CBC)
- To detect anaemia, which can falsely alter HbA1c values
7. Urine Examination
- Urine glucose and ketones
- Urine routine and microscopy (to detect proteinuria, UTI, haematuria)
8. C-peptide (if needed)
- To assess residual beta cell function; helpful to differentiate type 1 from type 2, or to assess eligibility for insulin therapy
Part B: Biochemical Reference Ranges
| Parameter | Reference Range | Target in Diabetes |
|---|---|---|
| Fasting Plasma Glucose | 70-100 mg/dL (3.9-5.6 mmol/L) | 80-130 mg/dL (ADA target) |
| Postprandial Glucose (2-hr) | <140 mg/dL (<7.8 mmol/L) | <180 mg/dL (ADA target) |
| HbA1c | <5.7% (non-diabetic normal) | <7.0% (ADA treatment target) |
| Fructosamine | 205-285 µmol/L | Reflects ~2-3 week average |
| Serum Creatinine | Male: 0.7-1.3 mg/dL; Female: 0.5-1.1 mg/dL | ----- |
| eGFR | >90 mL/min/1.73 m² (normal) | Monitor for decline |
| Urine Albumin-to-Creatinine Ratio (ACR) | <30 mg/g (normal) | <30 mg/g (target) |
| Microalbuminuria | 30-300 mg/g ACR | Warrants intervention |
| Overt proteinuria | >300 mg/g ACR | Nephrology referral |
| Total Cholesterol | Desirable: <200 mg/dL | <200 mg/dL |
| LDL Cholesterol | Optimal: <100 mg/dL | <70 mg/dL (high CV risk diabetics) |
| HDL Cholesterol | Male: >40 mg/dL; Female: >50 mg/dL | Higher is better |
| Triglycerides | Normal: <150 mg/dL | <150 mg/dL |
| VLDL Cholesterol | 2-30 mg/dL | ----- |
| TSH | 0.4-4.0 mIU/L | ----- |
| ALT | 7-56 U/L | ----- |
| AST | 10-40 U/L | ----- |
| BUN | 7-20 mg/dL | ----- |
Source: Tietz Textbook of Laboratory Medicine, 7th Ed.; ADA Standards of Care 2024
Part C: Alteration of Lipid Metabolism in Diabetes
The lipid metabolic derangements in diabetes are a direct consequence of insulin deficiency or resistance, and are particularly prominent in type 2 DM.
1. The Central Defect - Insulin Resistance and Lipolysis
In type 2 diabetes, insulin resistance in adipose tissue removes the normal anti-lipolytic action of insulin. Normally, insulin suppresses hormone-sensitive lipase (HSL) in adipocytes. When this action is lost:
- Unchecked lipolysis occurs in adipose tissue
- Free fatty acids (FFA) are massively released into the circulation
- The portal vein delivers these FFAs directly to the liver
Harrison's Principles of Internal Medicine 22E explains: "As a result of insulin resistance in adipose tissue, lipolysis and free fatty acid flux from adipocytes are increased and efficiently cleared by liver, leading to increased very-low-density lipoprotein (VLDL)-triglyceride synthesis in hepatocytes and secretion from liver."
2. Elevated VLDL and Hypertriglyceridemia
- The liver, flooded with FFAs, re-esterifies them into triglycerides
- These are packaged into VLDL and secreted into the bloodstream
- VLDL overproduction results in hypertriglyceridemia (TG typically >150-200 mg/dL)
- Insulin normally activates lipoprotein lipase (LPL) in peripheral tissues; insulin deficiency/resistance reduces LPL activity, impairing VLDL clearance
- This dual mechanism (overproduction + reduced clearance) drives elevated TG
3. Reduced HDL Cholesterol
- Elevated VLDL promotes cholesteryl ester transfer protein (CETP) activity
- CETP transfers cholesteryl esters from HDL to VLDL/IDL, depleting HDL
- Hypertriglyceridemia also increases hepatic lipase activity, which degrades HDL particles
- Result: low HDL-C (typically <40 mg/dL in men, <50 mg/dL in women)
4. Small, Dense LDL Particles (Atherogenic LDL)
- Although total LDL may be near-normal, the LDL composition shifts
- Triglyceride-enriched LDL particles are remodeled by hepatic lipase into small, dense LDL (sdLDL)
- sdLDL is more atherogenic because it:
- Penetrates the arterial intima more easily
- Is more susceptible to oxidation
- Has reduced receptor affinity, prolonging its circulation
As Harrison's notes: "This is also responsible for the dyslipidemia found in type 2 DM (elevated triglycerides, reduced high-density lipoprotein [HDL], and increased small dense low-density lipoprotein [LDL] particles)."
5. Diabetic Dyslipidemia - Summary Triad
| Lipid Abnormality | Direction | Mechanism |
|---|---|---|
| Triglycerides | ↑ Elevated | ↑ VLDL synthesis from FFA; ↓ LPL activity |
| HDL Cholesterol | ↓ Reduced | CETP-mediated HDL depletion; ↑ hepatic lipase |
| LDL (qualitative) | ↑ sdLDL | TG-enriched LDL remodeled to small, dense form |
| VLDL | ↑ Elevated | Excess hepatic FFA substrate; overproduction |
6. Additional Effects
- Ketogenesis: In insulin deficiency (especially type 1 DM or severe type 2), excess acetyl-CoA from beta-oxidation overwhelms the TCA cycle and is diverted to ketone body synthesis (acetoacetate, beta-hydroxybutyrate, acetone) - causing diabetic ketoacidosis (DKA)
- Hepatic steatosis (MASLD): When hepatic lipid synthesis exceeds export capacity, fat accumulates in the liver, causing fatty liver disease - a common comorbidity in type 2 DM
- Lipotoxicity: Elevated FFA and ceramide accumulation in non-adipose tissues (liver, pancreatic beta cells, skeletal muscle) further impairs insulin signaling and worsens beta cell function
7. Clinical Consequence
This diabetic dyslipidemia pattern (high TG + low HDL + small dense LDL) is highly atherogenic and is a major driver of the 2-4 fold increased cardiovascular risk seen in diabetic patients. This is why lipid monitoring and statin therapy form a cornerstone of diabetic management, even when LDL appears "normal" by standard testing.
Key Sources:
- Tietz Textbook of Laboratory Medicine, 7th Ed. - Table 47.3: Role of the Laboratory in Diabetes Mellitus
- Harrison's Principles of Internal Medicine, 22nd Ed. (2025) - Chapter 415: Diabetes Mellitus (Increased hepatic glucose and lipid production section)
- ADA Standards of Medical Care in Diabetes 2024 (HbA1c targets, screening intervals)
This is a shared conversation. Sign in to Orris to start your own chat.